{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122337","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.199856+00:00","generated_at":"2026-05-30T04:38:41.989804+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prelude Therapeutics Q3 net loss $32.3M; PRT3789 shows partial responses in SMARCA4-mutated cancers","bullets":["Cash, equivalents and marketable securities $153.6M; net loss $32.3M ($0.43/share) vs $30.6M prior year.","PRT3789 Phase 1: 4 confirmed partial responses in 26 evaluable SMARCA4-mutated NSCLC/esophageal patients; combo with docetaxel safe.","Initiated Phase 1 trial of oral SMARCA2 degrader PRT7732 in biomarker-selected SMARCA4-mutated cancers.","PRT2527 interim Phase 1 data in hematological malignancies to be presented at ASH Dec 2024; dose escalation completing this year.","Entered collaboration with Pfizer Ignite for SMARCA2 degrader development; Prelude retains full ownership."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122337","json":"https://secwatch.observer/filing/0000950170-24-122337.json","markdown":"https://secwatch.observer/filing/0000950170-24-122337.md","text":"https://secwatch.observer/filing/0000950170-24-122337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024122337/0000950170-24-122337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024122337/prld-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:38:41.989804+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}